TacticScale
Healthcare · Health Information Services · DOCS

What Doximity Does & How It Makes Money (DOCS)

Updated October 2026 · reflects Doximity's latest reported financials

Digital professional network and AI tools for U.S. medical professionals. Doximity makes money mainly from pharmaceutical manufacturers and health systems, which pay to put sponsored content in front of its medical-professional members and to use its tools, such as telehealth and scheduling software, for their organizations.

Doximity's story, moat and numbers — in a 3-minute visual book.

Explore Doximity on TacticScale →

How Doximity makes money

Doximity makes money mainly from pharmaceutical manufacturers and health systems, which pay to put sponsored content in front of its medical-professional members and to use its tools, such as telehealth and scheduling software, for their organizations.

What Doximity does

Doximity, Inc. is a San Francisco-based company, incorporated in 2010, that runs a digital platform for U.S. medical professionals. Members, including physicians, nurse practitioners, physician assistants and medical students, get a personalized newsfeed with medical articles, clinical trial and research results in short video form, peer updates, clinical discussions and Op-Med articles. The feed also carries sponsored content from pharmaceutical manufacturers and health systems. On top of its network, Doximity offers workflow tools for clinical work: Ask, a HIPAA-compliant AI assistant for looking up evidence-based medical information; Scribe, an AI-powered clinical documentation tool; telehealth tools for hospitals and health systems; and AMiON for on-call scheduling. Its customers are pharmaceutical manufacturers and healthcare systems that want to reach clinicians or equip them with these tools.

Products & services

What is Doximity worth?

On an owner-earnings DCF, Doximity's most-likely value is about $58 versus a recent price near $30 (91% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$19) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.

Verdict: Fairly priced — no edge
Owner-earnings fair value · recent price ≈ $30
Fair value (most likely)
$58
Range
$35–$108
No-growth floor
$19
Price
~$30

Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.

Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →

Sector Healthcare Industry Health Information Services HQ United States Ticker DOCS Official site

Related companies

Privia Health (PRVA) · DHC Software (002065.SZ) · Quest Diagnostics (DGX) · Danaher (DHR)

Understand Doximity in 3 minutes →